Literature DB >> 23519046

Concerns about pregabalin: further experience with its potential of causing addictive behaviors.

Maximilian Gahr1, Beate Franke, Roland W Freudenmann, Markus A Kölle, Carlos Schönfeldt-Lecuona.   

Abstract

Pregabalin (PRG) is approved for the treatment of neuropathic pain, partial seizures, and generalized anxiety disorder in many countries. Supported by case reports and a few studies there is an ongoing debate on PRG's potential to cause addictive behaviors. Considering that PRG is currently under investigation for the treatment of benzodiazepine dependence and withdrawal as well as relapse prevention in alcohol dependence, assessment of PRG's abuse and dependence potential is indispensable. We report the case of a 38-year-old female patient with borderline personality disorder and past alcohol abuse who developed PRG abuse. The patient took up to 800 mg PRG per day, initially administered to treat unspecific anxiety, and experienced euphoric feelings after PRG intake. In the further course, she increased the daily PRG dosage and consulted other physicians to receive additional PRG prescriptions. During reduction of PRG, the patient developed a moderate withdrawal syndrome with vegetative symptoms. Because of the early detection of the developing PRG abuse (4 months after first application of PRG), the development of PRG dependence was prevented. This case illustrates the possibility of PRG to trigger the development of addictive behaviors and should encourage physicians to be very careful when administering PRG to patients with current or past substance-related disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519046     DOI: 10.1097/ADM.0b013e3182872718

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  18 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

Review 2.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

4.  Pregabalin Use Disorder.

Authors:  Mehmet Bülent Sönmez
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

5.  A single injection of pregabalin induces short- and long-term beneficial effects on fear memory and anxiety-like behavior in rats with experimental type-1 diabetes mellitus.

Authors:  Alvaro Henrique Bernardo de Lima Silva; Debora Rasec Radulski; Gabriela Saidel Pereira; Alexandra Acco; Janaina Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2022-03-03       Impact factor: 3.584

6.  Factors associated with pregabalin dispensing at higher than the approved maximum dose.

Authors:  Robert Bodén; Björn Wettermark; Lena Brandt; Helle Kieler
Journal:  Eur J Clin Pharmacol       Date:  2013-10-19       Impact factor: 2.953

7.  A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

Authors:  Stefania Chiappini; Fabrizio Schifano
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 8.  Pharmacotherapy for anxiety and comorbid alcohol use disorders.

Authors:  Jonathan C Ipser; Don Wilson; Taiwo O Akindipe; Carli Sager; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2015-01-20

9.  Pregabalin dependence with pregabalin induced intentional self-harm behavior: A case report.

Authors:  S Ashwini; Dharmadhikari R Amit; Netto S Ivan; Pawar V Alka
Journal:  Indian J Psychiatry       Date:  2015 Jan-Mar       Impact factor: 1.759

10.  Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices.

Authors:  Moritz Knappich; Susanne Hörz-Sagstetter; Dirk Schwerthöffer; Stefan Leucht; Michael Rentrop
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.